| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5815491 | Neuropharmacology | 2012 | 12 Pages |
Abstract
⺠A GABA deficit is a hallmark of anxiety disorders and major depression. ⺠Modulators of α2, α3 GABAA receptors are effective, non-sedative anxiolytics. ⺠Modulators of α2, α3 GABAA receptors are proposed as novel antidepressants. ⺠Eszopiclone co-therapy supports the novel concept of GABAergic antidepressants.
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Hanns Möhler,